Clinical trials: Symptomatic COVID-19 Infection Laboratory-Confirmed
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
This phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04532372
- Testing
- Best Practice, Leflunomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04379518
- Testing
- Recombinant Interferon Alfa-2b, Rintatolimod
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)